Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Marcia Simpson Brose, MD PhD

Marcia Simpson Brose, MD PhD

faculty photo
Associate Professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania
Department: Otorhinolaryngology: Head and Neck Surgery
Graduate Group Affiliations

Contact information
Stellar Chance Building 8M

422 Curie Blvd.
Philadelphia, PA 19104
Office: 215-746-6344
Fax: 215-898-2136
B.A. (Biology)
Amherst College, Amherst, MA, 1986.
Ph.D. (Genetics and Developmental Biology)
Rockefeller University, New York, NY, 1994.
M.D. (Medicine)
Cornell University Medical College, New York, NY, 1995.
Permanent link
Perelman School of Medicine > Faculty > Search

Description of Research Expertise

Dr Brose is the director of the Thyroid Cancer Therapuetics Program and is a global leader in the development of the new field of thyroid cancer oncology. Her Phase II clinical trial of sorafenib in patients with advanced thyroid cancer lead to the successful completion of the first Phase III study, in this disease group (RAI refractory thyroid cancer). She was also one of the top accuers and lead site for the Phase III trial of cabozantinib for advance medullary thyroid cancer, which lead to FDA approval of this agent in November of 2012. Requested to speak and teach worldwide on her experience in the the use of novel agents to treat patients with all types of advanced thyroid cancer (Differentiate, Medullary, and Anaplastic), she is a global leader and educator to physicians and patients alike.

Dr. Brose also runs a lab in the field of translational studies in cancer genetics and genomics. Dr. Brose’s basic science research interest involves the identification of genetic abnormalities in the tumors of patients undergoing targeted therapies. Most of her research centers on translational projects directly related to samples obtained in the course of her clinical trial program. However, occasionally, science leads to leads in other tumor types. She currently has projects underway in thyroid cancer, breast cancer, lung cancer, colon cancer and esophageal cancer. Once identified, she is interested in understanding if these changes may identify tumors that may have or lack resistance to certain compounds. She has experience in the use of mice, drosophila, human tissue culture and clincal tissue samples. Her analytic tools include all types of PCR, RT-PCR, as well as the use of array comparative genomic hybridization (aCGH) and transcription profiling, taqman analysis, Q-RT-PCR and DNA sequencing on a regular basis, and whole and targeted genome sequencing. She also uses high resolution expression and SNP genotyping tetchnologies (Affymetrix and Illumina) to study the genetic basis of cancer. Dr. Brose provides the key correlative science for ongoing phaseI/II/III clinical trials at the University and internationally.

Description of Clinical Expertise

Treatment of Thyroid Cancer, PhaseI/II/III clinical trials, novel drug target discovery, and use of genetic testing in diagnosis, prognostication and prediction of resopnse to the treatment of cancer. Treatment of Rare Cancers of the Head and Neck.

Description of Other Expertise

Dr. Brose regularly instructs and mentors medical students,Internal Medicine and Head and Neck Surgerical residents, fellows (Hematology/Oncology, and Head and Neck Surgery) and post-doctoral PhD fellows who rotate through her lab in Hematology/Oncology and Cell genetics

Selected Publications

Cohen AB, Brose MS: Second-line treatment for advanced thyroid cancer: an indication in need of randomized clinical trials. J Clin Endocrinol Metab. 99(6): 1995-7, June 2014.

Brose,M.S., Nutting,C.M., Jarzab, B., Elisei, R., Siena, S., Bastholt,L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, YK, Sherman, SI, Smit, JWA, Chung, J., Kappeler, C., Pena, C., Molnar, I., Schlumberger, M.J., on behalf of the DECISION Investigators*: Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase III trial. The Lancet 14: 60421-9, April 2014 Notes: Corresponding Author.

Brose,M.S., Frenette,C.T., Keefe, S.M., Stein, S.M.: Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective. Seminars in Oncology 41(1): S1-S16, February 2014.

Schlumberger, M., Brose, M., Elisei,R., Leboulleux, S., Luster, M., Pitoia, F., Pacini, F.: Definition and management of radioactive iodine-refractory differentiated thyroid cancer (published online ahead of print). Lancet Diabetes and Endocrinology January 2014.

Brose, Marcia S: Thyroid Cancer Update: Conversations with Oncology Investigators: Bridging the Gap Between Research and Patient Care. Research to Practice. Neil Love MD (eds.). 4(1), October 2013 Notes: CME acredited activity/PODcast Distributed to Practicing Medical Oncologist across the US.

Elisei, R, Schlumberger, MJ., Mueller, S, Schöffski, P, Brose, MS, Shah, MH, Licitra, L, Jarzab, B, Medvedev, V, Kreissl, MC, Niederle, B, Cohen, EW, Wirth, LJ, Ali, H, Hessel, C, Yaron, Y, Ball, D, Nelkin, B, Sherman, SI: Cabozantinib in Progressive Medullary Thyroid Cancer. J Clin Oncol 31(29): 3639-46, October 2013.

Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R. : Efatutazone, an Oral PPAR-γ Agonist, in Combination with Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial. J Clin Endocrinol Metab 98(6): 2392-400, June 2013.

Lockhart*, A.C., Brose*, M.S., Kim*, E.S., Johnson, D.H., Peppercorn, J.F., Michels, D.L., Storm, C.D., Schuchter, L.M., and Rathmell*, W.K. (*Authors contributed equally to this work) : Physician and Stakeholder Perceptions of Conflict of Interest (COI) Policies in Oncology Journal of Clinical Oncology 31(13): 1677-1682, May (ePub Mar 25th) 2013.

Brose, MS, Nutting, C, Jarzab, B, Elisei, R, Siena, S, Bastholt, L, de la Fouchardiere, C, Pacini, F, Paschke, R, Shong, YK, Sherman, SI, Smit, JWA, Chung, J, Siedentop, H, Molnar, I, Schlumberger, M: Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase 3 DECISION trial (Plenary Presentation). ASCO Annual Meeting, Abstract #4 May 2013.

Sherman, SI, Cohen, EW, Schöffski, P, Elisei, R, Schlumberger, M, Wirth, L Mangeshkar, M, Aftab, DT, Clary, DO, and Brose M: Efficacy of Cabozantinib (Cabo) in Medullary Thyroid Cancer (MTC) Patients with RAS or RET Mutations: Results from a Phase 3 Study (Oral Presentation). American Society of Clinical Oncololgy Annual Meeting May 2013.

back to top
Last updated: 11/17/2014
The Trustees of the University of Pennsylvania